Frank Gleeson is the founder of Satellos (formerly ICo Therapeutics). Latest round: Seed. Based in Toronto, Ontario, Canada.
Frank Gleeson is the Co-founder and CEO of Satellos Bioscience Inc., a Canadian biotech company focused on treating Duchenne Muscular Dystrophy (DMD) and other degenerative muscle diseases. He previously served as the GlycoNet Chair and oversaw the company's transition from pre-clinical phases to initiating first-in-human safety studies.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide